Latest news with #CML
Mint
2 days ago
- Business
- Mint
How to transfer shares to a nominee in ICICI Direct demat account? Step-by-step guide
When an ICICI Direct demat account holder passes away then transferring shares to the registered nominee helps in a seamless and legally compliant transition of assets. Now to facilitate the same, the share transfer process is streamlined by ICICI Direct, provided documentation is in order. Transferring of shares to a nominee helps in avoiding legal delays, succession disputes and the need to obtain a court issued succession certificate. In case a nominee is registered with ICICI Direct then they become the rightful transferee of the deceased's securities, enabling direct access to demat stock portfolio and holdings. Check out the step by step guide to help nominees navigate the process efficiently. For single holders : Log into go to Settings → Trading Nominee, and then add nominee details (name, relation, ID, share %). Do note, up to three nominees can be registered with a total allocation of 100%. : Log into go to Settings → Trading Nominee, and then add nominee details (name, relation, ID, share %). Do note, up to three nominees can be registered with a total allocation of 100%. For joint holders: Download the nomination form from the ICICI Direct 'Downloads' section. Fill in the details carefully, get all holders' signatures, and submit it physically at the nearest ICICI branch. Keep a copy of the same with you and the acknowledgement provided by the bank for future reference. The nominee has to submit the following essential documents for initiating the transfer: Transmission Request Form, this form is available on the ICICI Direct website. Attested death certificate of the account holder. Self-attested PAN and ID proof of the nominee. Client Master List (CML) from nominee's DP if different from ICICI. Indemnity bond (only if nominee was not registered properly or account opened before 2016). Note: The list of documents listed above are illustrative in nature. For the updated list of documents required refer to the official website of ICICI Direct and reach out to the respective customer service team of the brokerage firm. All the relevant documents must be submitted either at the ICICI Direct depository participant office or an ICICI Bank branch. For more details on the same first refer to the official website of ICICI Direct and speak to their customer service team. Post verification, shares are transferred directly to the nominee's demat account. Furthermore, any errors such as signature mismatches or missing documents will result in delaying the process and will require resubmission. You can seek help, keep yourself updated and track progress from the following channels: Helpdesk email: helpdesk@ Official website: Support options: Availability of live chat, support ticket system, customer support and 'Contact Us' portal available under the Help section of the website. You can also download transmission and nominee related forms from the 'Downloads' page Requirement Description Nominee registered Online or through physical form Transmission form Filled and signed by nominee Death certificate Attested copy required PAN & ID proof Self-attested nominee documents CML (if external DP) With DP stamp and signature Indemnity (if applicable) Only for old accounts or unregistered nominees Hence, transferring shares to a legitimate nominee in an ICICI Direct demat account ensures smooth, dispute free and seamless asset transfer after the death of the account holder. ICICI Direct provides a simple and structured step by step process with clear documentation and digital support to help nominees complete the transfer effectively. Disclaimer: The information provided in this guide is for general awareness only and may be subject to change. For the latest and most accurate details, nominees are advised to refer to the official ICICI Direct website or contact their customer support.
Time of India
19-06-2025
- Health
- Time of India
Cancer fighter voted; why didn't you, Ludh West?
Ludhiana: A 68-year-old Veena Sood of Rishi Nagar, a former banker who is fighting chronic myeloid leukaemia (CML), a bone marrow and blood-related cancer, for the last thirty years, was among the first few voters at Polytechnic College polling booth in the company of her husband, Vinod Sood, who also retired from a bank. Veena Sood has been exercising her right to vote for 40-odd years now and both her husband and she are happy to vote. She claimed to have voted for a candidate she thinks will take care of development needs of the seat.
Yahoo
17-06-2025
- Business
- Yahoo
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) with a Buy rating and a $37.00 price target, implying a rise of about 60% from the current levels. The firm's confidence in the stock stems from favorable Phase 1 data for the company's chronic myeloid leukemia (CML) solution. The investment bank noted that ELVN-001's sustained efficacy data, presented during the European Hematology Association meeting, highlighted a 47% overall cumulative major molecular response (MMR) rate by 24 weeks and a 41% response in tyrosine kinase inhibitor (TKI)-resistant patients. These results surpassed the fourth-generation Scemblix by Novartis (SIX:NOVN) figures, with a difference of 10% and 32%, respectively. A biologist in a laboratory examining a microscope for small molecule inhibitors. The company is all set to launch a Phase 3 trial in 2026, which in itself is a $3 billion opportunity. If we look at the three-year return, Enliven Therapeutics, Inc. (NASDAQ:ELVN) exhibited a return of a whopping 1,980.18% in contrast to the 64.53% return by the market. Calling this simply an 'amazing' performance would be an understatement. Enliven Therapeutics, Inc. (NASDAQ:ELVN), headquartered in Boulder, Colorado, is a clinical-stage biopharmaceutical company. The company focuses on the recognition and development of small-molecule inhibitors to assist people living with cancer, improving survival and overall well-being. While we acknowledge the potential of ELVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Medscape
16-06-2025
- Health
- Medscape
Asciminib: High Responses in Second-Line Chronic-Phase CML
Asciminib, a first-in-class BCR - ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line therapy for patients with chronic-phase chronic myeloid leukemia (CML) who had suboptimal responses to earlier therapies. METHODOLOGY: The interim analysis on the single-arm, open-label study, conducted at 85 trial sites in the US, included 101 patients with chronic-phase CML who discontinued a prior TKI due to intolerance or suboptimal responses. Patients were treated with at least one dose of asciminib 80 mg once daily. If BCR - ABL levels were above 1% at week 24, the dose was increased to 200 mg daily, and if BCR - ABL levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. - levels were above 1% at week 24, the dose was increased to 200 mg daily, and if - levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. Those with any grade 3 or 4 or persistent grade 2 toxicities that were refractory to optimal management were ineligible for dose escalations. Reasons for prior treatment discontinuation were due to a lack of efficacy in 56.4% and intolerance in 43.6% of patients. TAKEAWAY: At week 24, a major molecular response was achieved by 44.4% of patients, with 25.4% achieving a deep molecular response (MR4 or better). In all, 11.1% of patients were given dose escalations upon failing to achieve response milestones. Among 101 patients receiving at least one dose, asciminib was well tolerated by most patients. Asciminib's safety profile was that observed in previous studies, with no new or worsening safety findings observed. Grade 3 and higher adverse events (AEs) included hypertension (8.9 %), thrombocytopenia (6.9%), and neutropenia (5.9%). AEs overall led to dose adjustment or interruption in 26.7% of patients and discontinuation in four patients. IN PRACTICE: 'Asciminib, in contrast with other FDA-approved TKIs, binds to the ABL myristoyl pocket, which may reduce off-target effects compared to the other competitive TKI's,' said first author David Jacob Andorsky, MD, of the Rocky Mountain Cancer Centers, US Oncology Research, Boulder, Colorado. 'Results from ASC2ESCALATE, the first prospective trial of asciminib in second-line chronic-phase CML with dose escalation in patients not achieving response milestones, further support asciminib as a treatment option in second-line chronic-phase CML,' he said. 'The outcomes in patients with asciminib dose escalations continue to be explored, with analyses planned for future presentations,' Andorsky noted. SOURCE: The analysis was presented at the American Society of Clinical Oncology (ASCO) 2025 in Chicago. DISCLOSURES: This study was sponsored by Novartis Pharmaceuticals. Andorsky reported having relationships with AbbVie, AstraZeneca, Celgene, and Novartis.
The Hindu
15-06-2025
- Health
- The Hindu
Our body's crimson tide: the evolving treatment landscape in haematology
Historically, treatment for blood cancers, relied heavily on chemotherapy. However, this 'carpet bombing' approach, apart from destroying cancer cells also affects healthy, rapidly-dividing cells. This can lead to significant side effects like vomiting ,immunosuppression, hair loss and anaemia. While chemotherapy remains vital, the goal has always been more precise, less toxic options. A deeper understanding of cancer cell biology has paved the way for 'targeted therapy'—drugs designed as 'surgical strikes' against molecular targets predominantly found on or within cancer cells. This approach aims for greater efficacy with a more manageable side-effect profile, sparing normal cells to a larger extent. Imatinib - the dawn of targeted therapy in haematology A pivotal moment in targeted therapy arrived with Imatinib, approved in 2001 for Chronic Myeloid Leukaemia (CML). CML is driven by the Philadelphia chromosome, a genetic abnormality creating the BCR-ABL fusion gene that fuels uncontrolled white blood cell proliferation. Before Imatinib, CML was often fatal within years. Imatinib was designed to block the activity of this BCR-ABL protein. Its success was revolutionary, transforming CML from a deadly disease into a manageable chronic condition for most patients, who could now achieve long-term remission and a good quality of life with a daily pill. This validated the concept of molecularly targeted therapy and spurred massive research into similar approaches for other cancers, heralding a new frontier in cancer treatment . Harnessing the immune system --the rise of immunotherapy in haematology Our immune system, with its innate (first-line, non-specific) and adaptive (specialised, memory-forming) arms, is designed to eliminate threats, including cancerous cells. Immunotherapy aims to boost or re-engage the patient's immune system to fight cancer. Various types of antibody based therapies such as Monoclonal Antibodies (mAbs) antibodies target specific antigens on cancer cells. Bispecific Antibodies (e.g., BiTEs - Bispecific T-cell Engagers)have two binding sites-- one for a cancer cell antigen and another for a T-cell (an immune killer cell). Antibody-Drug Conjugates (ADCs) are 'armed antibodies' and combine an antibody's targeting precision with a potent cytotoxic drug . These immunotherapies offer highly effective options ,which earlier approved for resistant cancers ,are being increasingly used in frontline settings. For thousands battling life-threatening blood cancers and other devastating diseases, a Bone Marrow Transplant (BMT) offers a beacon of hope – a potential cure when other treatments have failed. This remarkable medical procedure involves replacing a patient's diseased or damaged bone marrow with healthy stem cells from the patient (autologous BMT) or a healthy donor (allogenic BMT) . Recent advances in BMT BMT is a critical treatment option for a range of blood conditions. These include benign conditions such as sickle cell anaemia, thalassemia, aplastic anaemia, inherited immune deficiency and metabolic disorders as well as malignant conditions like high risk acute leukemias, myelodysplastic syndrome, relapsed leukemias, myelomas and relapsed /refractory lymphomas. Earlier, allogenic bone marrow transplant were done only with HLA matched donors (related or unrelated) .The probability of finding a matched donor was only 30%. Now however, haploidentical (Haplo) BMT, a groundbreaking approach, allows for transplants using donors (typically family members like parents or children) who are only a half-match for the patient's HLA involves the use of PTCY - Post transplant cyclophosphamide, where chemotherapy is administered on day +3 and day +4 after infusion of the stem cells. This has dramatically increased donor availability, meaning most patients who need a transplant can now find a suitable donor. Traditionally, BMT involved high-dose chemotherapy and/or radiation (myeloablative conditioning) to wipe out the patient's marrow. Reduced Intensity Conditioning (RIC) Transplant regimens use lower, less toxic doses, making transplants an option for older patients or those with other health conditions who might not tolerate aggressive conditioning. This relies more on the graft versus leukemia effect, where the donor cells act against the cancer of the recipient . Improved Graft Manipulation: Scientists area also developing sophisticated ways to process donor stem cells before infusion such as TCR α/β depletion which removes specific T-cells (T-cell receptor alpha/beta cells) from the donor graft that are primarily responsible for causing graft versus host disease (GVHD). With ongoing research and innovation, the future promises even better outcomes, reduced side effects, and wider applicability, offering a renewed lease on life to countless individuals around the world. CAR T-cell therapy: living drugs to combat cancer Chimeric Antigen Receptor (CAR) T-cell therapy is a groundbreaking immunotherapy that engineers a patient's own T-cells into potent cancer-killing 'living drugs.' The process involves collecting a patient's T-cells, genetically modifying them in the lab to express a CAR that recognises a specific antigen on their cancer cells (e.g., CD19 on B-cell leukaemias/lymphomas), expanding these engineered cells, and then infusing them back into the patient. Once infused, CAR T-cells seek out and destroy cancer cells expressing the target antigen. This therapy has achieved unprecedented success in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia and certain non-Hodgkin lymphomas, leading to high remission rates and several FDA-approved products. However, challenges include significant potential side effects like Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS), along with high manufacturing complexity and cost. Gene therapy, AI and the importance of foundational clinical skills Gene therapy offers curative potential for inherited haematological disorders by modifying a patient's cells, often by introducing a functional gene or correcting a faulty one. Haematopoietic stem cells (HSCs) from bone marrow are prime targets, as modified HSCs can repopulate the marrow with corrected cells, offering a permanent solution. Significant progress has been made in diseases such as sickle cell disease, Beta-thalassemia and Hemophilia A in this regard. While transformative, challenges like long-term durability, cost, and access remain. Artificial Intelligence (AI) is emerging as a powerful tool in haematology, capable of analysing vast and complex datasets to enhance diagnosis, treatment, and research. Key applications include: AI-powered diagnostics: AI algorithms analyse blood smears and bone marrow biopsies to identify and classify cells with high accuracy, potentially assisting pathologists and improving diagnostic efficiency. AI also helps interpret complex genomic data from NGS. Accelerating drug discovery: AI can identify novel therapeutic targets, predict drug efficacy and toxicity, and repurpose existing drugs for haematological conditions, streamlining development. It can also aid in patient stratification for trials and accelerate data analysis, potentially speeding up drug approvals. AI can also integrate diverse patient data to predict individual responses to therapies, helping clinicians choose optimal treatment plans. It is poised to act as an 'AI physician assistant,' augmenting human expertise rather than replacing it, leading to more precise and personalised care. In this era of remarkable technological progress, from gene editing to AI, it's vital to remember that the foundations of good medical practice such as thorough history taking, comprehensive physical examinations and focussed investigations are paramount in arriving at the right diagnosis. The future of haematology lies in the synergistic integration of traditional medical wisdom and cutting-edge technology, ensuring holistic patient care and continued progress against blood disorders. This is the second story of the two-part series. You can read the first story here. (Dr. Steve Thomas, is a clinical haemato-oncologist and BMT physician at Sri Ramachandra Medical College, Porur, Chennai. stev07thomas@
